JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Cerrado

1.22 2.52

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.2

Máximo

1.22

Métricas clave
By Trading Economics
Ingresos	2.7M -24M
BPA	-0.354
Empleados	49
EBITDA	-5.3M -28M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+120.66% upside

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-6.2M 75M
Apertura anterior	-1.3
Cierre anterior	1.22

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

30 abr 2026, 23:08 UTC

Ganancias

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 abr 2026, 23:07 UTC

Ganancias

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 abr 2026, 22:20 UTC

Ganancias

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 abr 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 abr 2026, 23:47 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

30 abr 2026, 23:47 UTC

Charlas de Mercado

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 abr 2026, 23:27 UTC

Charlas de Mercado

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 abr 2026, 23:22 UTC

Ganancias

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 abr 2026, 23:20 UTC

Charlas de Mercado

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 abr 2026, 22:52 UTC

Ganancias

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 abr 2026, 22:33 UTC

Ganancias

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 abr 2026, 22:32 UTC

Ganancias

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 abr 2026, 22:32 UTC

Ganancias

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 abr 2026, 22:24 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 abr 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 abr 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 abr 2026, 22:23 UTC

Adquisiciones, fusiones, absorciones

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 abr 2026, 22:11 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 abr 2026, 22:11 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

30 abr 2026, 22:11 UTC

Charlas de Mercado

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 abr 2026, 22:05 UTC

Ganancias

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 abr 2026, 21:57 UTC

Ganancias

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 abr 2026, 21:56 UTC

Ganancias

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 abr 2026, 21:56 UTC

Ganancias

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 abr 2026, 21:55 UTC

Ganancias

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 abr 2026, 21:54 UTC

Ganancias

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 abr 2026, 21:54 UTC

Ganancias

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 abr 2026, 21:53 UTC

Ganancias

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 abr 2026, 21:49 UTC

Ganancias

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 abr 2026, 21:49 UTC

Ganancias

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc previsión

Precio Objetivo

By TipRanks

120.66% repunte

Estimación a 12 Meses

Media 2.67 USD 120.66%

Máximo 3 USD

Mínimo 2 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.